home / stock / rgls / rgls articles
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Regulus Therapeutics, Inc. (NASDAQ:RGLS) shares were initially trading higher Monday before pulling back and turning negative after the company ann...
Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial re...
Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance. Asana reported quarterly losse...
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 1% on Tuesday. The Dow traded up 0.48% to 38,955.84 whil...
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 100 points on Tuesday. Following the market opening Tuesday, the D...
Tuesday, Regulus Therapeutics Inc (NASDAQ:RGLS) released topline results from the second cohort of patients in its Phase 1b multiple-asce...
Regulus Therapeutics Inc (NASDAQ: RGLS) released topline results from the first cohort of patients in its Phase 1b Multiple-Ascending Dose (MA...
News, Short Squeeze, Breakout and More Instantly...
Regulus Therapeutics Inc. Company Name:
RGLS Stock Symbol:
NASDAQ Market:
Regulus Therapeutics Inc. Website:
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire Continued mechanistic dose resp...
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes PR Newswire SAN DIEGO , June 4, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and devel...
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer PR Newswire SAN DIEGO , May 16, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of inn...